Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1558-1560, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivor, L. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivor, L. P.

Clinical Chemistry, Vol 42, 1558-1560, Copyright © 1996 by American Association for Clinical Chemistry

A parallel revolution: payment for new in vitro diagnostic technologies

LP Ivor
Del Mar, California, USA. livor@aol.com.

To secure a successful product in today's era of cost containment, manufacturers and developers of new in vitro diagnostic technologies must consider payment issues--coverage and reimbursement by healthcare insurers--as critical market forces that must be addressed in the business plan. Similar to the regulatory hurdles involving 510(k)s and premarket applications, the requirements for payment are related to the unique features of the technology, its costs, and its effect on clinical outcomes. Because cost containment continues to be a driving force for change in healthcare, the business plan must not only include strategies for optimal payment at the product's introduction, but also contain provisions for continuous monitoring of the payment environment throughout the product's life cycle.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.